Novocure Receives FDA Approval for Second Generation Optune System Second generation Optune system is less than half the weight and size of first generation Optune system New system aims to make ...

The FDA has approved a lighter and more convenient version of the tumor-treating field device Optune for patients with glioblastoma multiforme. The FDA has approved a lighter and more convenient ...

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure, a commercial stage oncology company, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Optune™, a Tumor ...

St. Helier, NJ's Novocure ($NVCR) submitted a PMA supplement with the FDA, in hopes of marketing an upgraded version of its noninvasive Optune system to treat ...

The FDA approved Novocure’s ($NVCR) PMA supplement application for its second-generation Optune system to treat glioblastoma. The device is a smaller, lighter ...

Novocure Ltd. (NASDAQ:NVCR), a cancer therapy company yesterday announced that the FDA approved its second generation Optune system. The new Optune system is a lightner Tumor Treating Fields delivery ...

Shares of Novocure continue to trounce the overall markets return. The performance is justified as the company remains in the early innings of its growth ascendancy. The secret to the stellar gains is ...

Shares drop sharply in response to a disappointing second-quarter earnings report. So what: The number of active patients using the company's Optune system continues to grow at impressive rates, ...

NovoCure Ltd., which makes a device that uses electrical fields to fight a common form of brain cancer, has disclosed plans for an initial public offering. NovoCure’s Optune system is a treatment for ...